Aspirin in Dilated Cardiomyopathy
Aspirin should only be prescribed for patients with dilated cardiomyopathy (DCM) if there is a clear indication for secondary prevention of atherosclerotic disease—it is NOT routinely indicated for idiopathic DCM alone. 1
Primary Recommendation
The Canadian Cardiovascular Society guidelines explicitly state that ASA is not required for patients with idiopathic dilated cardiomyopathy and no other indication for ASA 1. This is the most direct guidance available and should frame your decision-making.
When to Prescribe Aspirin in DCM
Use aspirin (81-325 mg daily, preferably 81 mg) if:
- The patient has established atherosclerotic cardiovascular disease requiring secondary prevention 2, 1
- There is documented coronary artery disease
- The patient is diabetic with established CVD 2
The lower dose (81 mg) is preferred as it carries lower risk of gastrointestinal complications 1.
When NOT to Use Aspirin in DCM
Avoid aspirin in:
- Pure idiopathic DCM without atherosclerotic disease 1
- Patients already on anticoagulation (warfarin/DOACs) for other indications—combination therapy is NOT routinely recommended (Class III, Level A) 1
- Unstable heart failure patients, as high-dose aspirin may worsen heart failure similar to NSAIDs 1
Critical Pitfalls
High-dose aspirin (>325 mg) shares risks with NSAIDs and may aggravate heart failure, particularly in unstable patients 1. This is a commonly overlooked issue that can lead to clinical deterioration.
What About Anticoagulation Instead?
For DCM patients in sinus rhythm, anticoagulation is not routinely recommended but should be considered for 1:
- Demonstrated intracardiac thrombus
- Spontaneous echocardiographic contrast
- Severe LV systolic dysfunction where thrombus cannot be excluded (Class IIa, Level C)
Recent evidence shows that when LV thrombus is present in DCM, both warfarin and DOACs have comparable efficacy for thrombus resolution, though thrombus persistence/progression correlates with worse outcomes 3.
The Evidence Gap
Research shows thromboembolism risk in DCM ranges from 1.5-3.5 per 100 patient-years 4, but no randomized data support routine aspirin prophylaxis in DCM without additional atherosclerotic indications 4. One observational study even demonstrated ventricular thrombus formation despite aspirin and anticoagulation therapy in a patient with markedly elevated platelet activation 5.